What is GERN's current stock price?

GERN (Geron Corporation) is currently trading at $1.28 with a market cap of $821.1M.

What sector is Geron Corporation in?

Geron Corporation (GERN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GERN a good stock to buy?

Analysts have a Buy consensus on GERN with a price target of $5.89. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GERN Geron Corporation

Healthcare

$1.28+1.59%ClosedMarket Cap: $821.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.74

P/S

4.19

EV/EBITDA

-24.63

DCF Value

$-6.99

FCF Yield

-15.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

86.6%

Operating Margin

-19.1%

Net Margin

-35.5%

ROE

-28.9%

ROA

-13.0%

ROIC

-7.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$51.8M	$-3.6M	$—
Q4 null	$48.0M	$-31.1M	$—
FY null	$183.9M	$-85.8M	$—
Q3 null	$47.2M	$-18.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.89

Target (Median)

$6.00

Target Range

$4.00 - $8.00

1 Strong Buy3 Buy1 Hold1 Sell0 Strong Sell

NeedhamBuy

2025-11-05

Trading Activity

Insider Trades

View All

Williams Timothyofficer: EVP and Chief Legal Officer

SellTue Apr 14

Williams Timothy

SellTue Apr 14

Spiegel Robert J.director

SellWed Apr 01

Chinoporos Constantinedirector

SellThu Mar 26

Chinoporos Constantine

SellThu Mar 26

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.68

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Peers